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Celiac disease (CD) is a chronic enteropathy elicited by a Th1 response to gluten
peptides in the small intestine of genetically susceptible individuals. However, it remains
unclear what drives the induction of inflammatory responses of this kind against harmless
antigens in food. In a recent work, we have shown that the p31-43 peptide (p31-43)
from α-gliadin can induce an innate immune response in the intestine and that this may
initiate pathological adaptive immunity. The receptors and mechanisms responsible for
the induction of innate immunity by p31-43 are unknown and here we present evidence
that this may reflect conformational changes in the peptide that allow it to activate
the NLRP3 inflammasome. Administration of p31-43, but not scrambled or inverted
peptides, to normal mice induced enteropathy in the proximal small intestine, associated
with increased production of type I interferon and mature IL-1β. P31-43 showed a
sequence-specific spontaneous ability to form structured oligomers and aggregates
in vitro and induced activation of the ASC speck complex. In parallel, the enteropathy
induced by p31-43 in vivo did not occur in the absence of NLRP3 or caspase 1 and
was inhibited by administration of the caspase 1 inhibitor Ac-YVAD-cmk. Collectively,
these findings show that p31-43 gliadin has an intrinsic propensity to form oligomers
which trigger the NLRP3 inflammasome and that this pathway is required for intestinal
inflammation and pathology when p31-43 is administered orally to mice. This innate
activation of the inflammasome may have important implications in the initial stages of
CD pathogenesis.
Keywords: enteropathy, celiac disease, inflammasome, caspase-1, p31-43, gliadin peptides, innate immunity,
small intestine damage
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INTRODUCTION
Celiac disease (CD) is the commonest form of immune mediated
enteropathy throughout the world and is caused by an antigen-
specific CD4+ T cell response to wheat gluten in genetically
susceptible individuals (1). Although a gluten-specific Th1
response is essential for the disease, there is increasing evidence
that an initial innate immune response is necessary to trigger the
local inflammation that drives adaptive immunity (2). As gluten
proteins are not fully digested by gastrointestinal enzymes, long
gluten-derived peptides remain in the gut lumen. Among these
peptides, the α-gliadin 56–88 peptide (commonly named 33mer),
is the model peptide for studying the adaptive response in CD
(3). One candidate for driving this innate immune response is
the gluten-derived peptide, α-gliadin 31-43 (p31-43) (4) which
has been shown to induce several proinflammatory effects in vivo
both in humans (5), and mice (6). Although p31-43 is thought
to act by triggering an intracellular stress response because it
interferes with endosomal trafficking (5), no receptor has been
identified for this peptide (7) and therefore it is unknown if and
how it can be recognized by the sensors of the innate immune
system.
To unveil how this peptide induces inflammation and tissue
damage, we aimed to evaluate whether a particular conformation
may be responsible for its biological effects.
The special aminoacidic sequence of gluten proteins (8)
as well as of shorter peptides as 33mer, confers uncommon
conformational features such as polyproline II conformation and
the occurrence of oligomers (9, 10). In the case of p31-43, the
structure has not been studied.
Oligomeric structures and fibrils are triggers of inflammation
through activation of the NLRP3 inflammasome leading to
production of active IL-1β and cell death by pyroptosis.
Nanostructures may alter intracellular organelles (such as
endoplasmic reticulum and mitochondria) and release danger
signals which can be sensed by the NLRP3 inflammasome (11).
Here, we show that p31-43 gliadin has an intrinsic propensity
to form oligomeric structures that allow it to trigger the
NLRP3 inflammasome, leading to caspase 1 dependent intestinal
inflammation and pathology when administered orally to mice.
MATERIALS AND METHODS
Mice
Male C57BL/6 were purchased from the Animal Care facility
of the Veterinary Faculty from National University of La
Plata, while caspase1/11−/− (B6N.12952-Casp1tmflv/J) and
NLRP3−/− (B6.12956-Nlrp3tm1Bhk/J) mice were obtained from
the Transgenic and Experimental Animal Unit of the Institut
Pasteur de Montevideo (Uruguay). All mice were housed
under specified pathogen free conditions and allowed access to
autoclaved food and water ad libitum. Mice were used at 7 weeks
Abbreviations: NLRP3, nucleotide-binding oligomerization domain leucine rich
repeat and pyrin domain-containing protein 3; ASC, the adaptor protein
apoptosis-associated speck-like protein containing a CARD (caspase-recruitment
domain).
of age and all experimental procedures were performed under
appropriate local ethical guidelines. Experimental protocols were
approved by the Institutional Animal Care and Use Committee
of the Facultad de Ciencias Exactas, Universidad Nacional La
Plata (Protocols 002-05-15 and 009-27-17) or by the Animal
Ethics Committee of the Institut Pasteur (Montevideo) in
accordance with national law 18.611 and international animal
care guidelines regarding laboratory animal protocols (protocol
011-17).
Peptides
The following peptides were synthesized at >95% purity by
GeneCust, Luxembourg: p31-43 (LGQQQPFPPQQPY), non-
related peptide (NRP, LDPLIRGLLARPACALQV), scrambled
sequence peptide (SP, YQPLFQPQGPQPQ), and inverted
sequence peptide (IP, YPQQPPFPQQQGL).
Induction of Enteropathy by Administration
of Peptides
Peptides were administered in a volume of 100µl by intraluminal
injection into the small intestine 2 cm from the pylorus after
laparotomy under isofluorane anesthesia as described previously
(6). Control mice received phosphate saline buffer (PBS). After
surgery, fluid replacement was administered and mice were
monitored until recovery. For oral administration, peptides, or
PBS were given in 200 µl using a curved oral gavage needle (22G,
3.8 cm).
Four or 16 h post-inoculation, mice were euthanized, and
intestinal samples were collected for mRNA evaluation and
histological analysis. To inhibit caspase-1 activity in vivo, mice
received 8 mg/kg Ac-YVAD-cmk (InvivoGen, United States) in
DMSO (5% v/v) or DMSO alone intraperitoneally 30min before
oral administration of peptide. After 16 h, mice were euthanized
and intestinal samples were collected for histological analysis.
Histological Evaluation
Sections of proximal small intestine of mice were fixed in 4%
w/v formalin, embedded in paraffin, and stained with H&E for
histological evaluation using a Nikon Eclipse Ti fluorescence
microscope with X-Cites Series 120 Q light source. Images were
taken with a Nikon Digital Sight DS Ri1 camera using Nis-
Elements software and measurements were performed using
Image J software. Sections were scored in a blinded fashion,
with at least 30 villus:crypt ratios assessed in each mouse, while
intraepithelial lymphocytes (IELs) were counted in 10 randomly
chosen villus tips and expressed as IELs/100 enterocytes.
Real Time PCR
Small Intestinal samples from mice were stored in RNA Later
(Ambion, United States) at −20◦C until use and RNA was
extracted using Illustra RNA spin mini RNA isolation Kit (GE
Heathcare). cDNA was synthesized from 2 to 5 µg RNA using
M-MLV Reverse Transcriptase (Invitrogen) and Real Time PCR
was performed using SYBER green PCR Master mix (BioRad)
for 40 cycles, with the following primers: HPRT-f 5′-CAATGC
AAACTTTGCTTTCC-3′; HPRT-rev 5′- CAAATCCAACAA
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AGTCTGGC- 3′; IFNβ-f 5′-AATGGAAAGATCAACCTCAC-
3′; IFNβ-rev 5′-AAGGCAGTGTAACTCTTCTG-3′. HPRT was
used as an internal control to normalize the expression levels.
All results were expressed as fold increase of each treatment vs.
the mean of PBS treated samples for each time point using the
2−11Ct method). All samples were assessed in triplicate.
Activation of the Inflammasome in vitro
ASC reporter cell line (InvivoGen) were kindly provided by Dr.
Rumbo M (IIFP). Cells were cultured in RPMI 1640, 25mM
HEPES/2mM L-glutamine/10% heat-inactivated fetal bovine
serum/50 U/ml penicillin, 50µg/mL streptomycin at 37◦C in 5%
CO2. 180 µl aliquots of 2 × 10
6 cells/mL were added to a 96-
well plate and allowed to adhere for 1 h, before 20 µl of LPS
at 1µg/mL was added for 3 h to “prime” the inflammasome.
Medium was then removed and replaced by fresh medium
containing 50 or 100µg/mL p31-43 or inverted peptide, before
the cells were cultured for 16 h at 37◦C. After stimulation, the
cells were washed with PBS and fixed with 2% PFA for 15min at
37◦C and stained with 1µg/mL DAPI to visualize the nucleus.
ASC specks were then imaged by assessing GFP expression using
a Nikon Eclipse Ti fluorescence microscope and Nikon Digital
Sight DS Ri1 camera with Nis-Elements. Results were expressed
as ASC positive cells/100 cells. All treatments were performed in
triplicate.
Western Blot
Fresh small intestine tissues from individual mice were lysed
and protein extracts were quantified using the BCA kit
(Thermo, Rockford, United States). Protein samples (30µg/lane)
were separated by sodium dodecyl sulfate polyacrilamide gel
electrophoresis on 10 or 12.5% gels and transferred onto
nitrocellulose membranes. The membranes were blocked with
5% fat-free dry milk in TBST 0.1% at 37◦C for 1 h and
incubated with the following primary antibodies: anti-caspase
1 (1/150, SC-56036, Santa Cruz), anti-IL-1β (1/100, P420B,
Invitrogen), anti-β-actin (1/2000, Ab8227, Abcam) at 4◦C
overnight. After washing, membranes were incubated with
horseradish peroxidase (HRP)-conjugated secondary goat anti-
rabbit antibody (1/2000, 1706515, BioRad), or horseradish
peroxidase (HRP)-conjugated secondary anti-mouse antibody
(1/3000, Ab6789, Abcam) at 37◦C for 1 h, and visualized using
the enhanced chemiluminescent reagent (GE Healthcare). The
relative levels of the target protein to the control β-actin were
determined using ImageJ software.
Circular Dichroism
Circular Dichroism spectra of peptide solutions were recorded on
a Jasco J-810 spectrometer polarimeter using a Peltier system as
temperature controller. Five scans were acquired in the range of
190–250 nm at 4◦C, using a scanning speed of 50 nm/min. The
spectra were obtained employing 1 and 0.1mm quartz cuvettes.
Blank scans were subtracted from the spectra and smooth noise
reduction was applied when needed using a binomial method
(12). The data were expressed as the mean residue molar
ellipticity in deg cm2 dmol−1. Graphics were represented using
Origin Software (OriginLab).
Transmission Electron Microscopy
Three aliquots of 50µM and three of 100 uM concentration
of p31-43 were prepared in MilliQ water from a 3mM mother
solution of the peptide. These solutions were deposited onto
copper grids (200 mesh) coated with Formvar. After 5min the
excess fluid was removed by capillarity and the samples were
negatively stained with 2% uranyl acetate in water for 2min. After
removal of excess fluid, the samples were allowed to dry and
visualized using a JEOL 100CX II microscope operating at 100
kV.
Modeling of Peptide Conformation in silico
Molecular dynamics simulations were performed at a coarse
grained level employing the SIRAH force field (13). The initial
structure of p31-43 was arbitrarily assumed to be a canonical α-
helical conformation, with the N- and C-terminal amino acids
considered as zwitteronic. An isolated peptide was simulated
for 500 ns, setting a salt concentration (NaCl) to 150mM.
Four different structures were randomly chosen within this
time window to serve as starting conformers and 50 copies of
these conformers were disposed in a computational solvation
box at a minimum distance of 4 nm between their centers of
mass and simulated for 5 µs. Both the monomer and 50-mer
simulations were performed with GROMACS 4.6.7 in the NPT
ensemble at 310K. The last 100 ns of each simulation were
used for analysis and secondary structure was calculated using
SIRAH tools (14) while interpeptide contacts were computed
with g_mindist included in the GROMACS analysis tools. The
aggregation was monitored as a function of the formation and
sizes of clusters. A cluster was defined when the distance between
two atoms of different peptides was <0.4 nm and mean cluster
size (MCS) was calculated as MCS = (
∑
Ni = 1 CSi,t) /N, where
CSi, t is the cluster size to which peptide i belongs at time t, and
N is the total number of peptides (14).
Statistical Analysis
Statistical analysis was performed with Graph-Pad Prism
software (San Diego, United States). When two groups were
compared, an unpaired Student’s t-test was used, while a one-
way ANOVA, post-test Bonferroni was used whenmore than two
groups were compared. P < 0.05 was considered significant. Data
are displayed as means± 1 SEM.
RESULTS
Intraluminally Delivered p31-43 Gliadin
Peptide Induces Mucosal Damage in a
Sequence Specific Manner
To explore how the sequence and structure of p31-43
might influence its ability to induce enteropathy, we first
compared the effects of intraluminal administration of the
native peptide (LGQQQPFPPQQPY) and synthetic peptides
with an inverted (YPQQPFPPQQQGL) (IP) or scrambled
sequence (YQPLFQPQGPQPQ) (SP). This route was used to
avoid potentially complicating effects of the peptides being
differentially sensitive to cleavage by gastrointestinal enzymes.
An unrelated peptide (NRP) and PBS (vehicle) were also
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FIGURE 1 | Gliadin peptide p31-43 induces small intestine pathology in a sequence-specific manner. C57BL/6 mice were injected intraluminally with native p31-43,
inverted sequence peptide (IP), scrambled sequence peptide (SP), non-related peptide (NRP), or PBS. The ratio between villus length and crypt depth (V/C) (right axis)
and the numbers of intraepithelial lymphocytes/100 enterocytes (left axis) were determined on H&E stained sections of proximal small intestine 16 h after
administration of 10 µg (A) or 1 µg (B) peptide/mouse. IFNβ mRNA was assessed by RT-qPCR on whole proximal small intestine samples 4 h after treatment. Results
shown are means ± 1 SEM for 5 mice per group. *p < 0.05 by ANOVA, post-test Bonferroni.
used as controls. As we have shown previously (6), 16 h after
intraluminal administration of 10µg native p31-43, mice showed
evidence of pathology in the upper small intestine, with a lower
villus length/crypt depth (V/C) ratio and a higher number of
intraepithelial lymphocytes (IELs) compared with PBS controls
(Figures 1A,B). p31-43 treated mice also showed increased
expression of mRNA for IFNβ in the mucosa 4 h after treatment
(Figure 1A). Similar findings were observed when mice were
treated with 10 times less amount of native p31-43 (Figure 1B),
suggesting that this peptide has a potent biological in vivo effect
on the small intestinal mucosa. However, none of these intestinal
changes were observed after administration of 10 µg of the
inverted or scrambled peptides, indicating that the effects of p31-
43 are sequence-specific and not a consequence of inflammation
due to the surgical procedure.
p31-43 Peptide Adopts a Polyproline II
Structure and Self-Organizes in Oligomers
Together with our previous findings that p31-43 activates the
MyD88 and the type I IFN signaling pathways (6), the results
above indicate that p31-43 is a potent trigger of the innate
immune response and that its sequence is critical for this
effect. For this reason, we hypothesized that p31-43 may adopt
a particular secondary structure that is responsible for its
biological effects. To assess the secondary conformation of p31-
43, Circular Dichroism analysis was performed on 10, 50, and
100µM solutions of the peptide at 4◦C, concentrations that are
in the range used for the in vivo studies (Figure 2A). Under
these conditions, p31-43 generated a signal characteristic of a
polyproline II structure, as shown by a negative band near 203 nm
and a positive band at 225 nm (15). When the concentration
of p31-43 was increased, a small hypochromic displacement of
the negative and the positive bands was detected, indicating a
concentration dependent, self-organization process (16). When
the scrambled and inverted peptides were analyzed at 100µM
concentration for comparison, the scrambled peptide showed
only a negative band at 200 nm, indicative of a random coil
structure. Although the inverted peptide showed evidence of a
polyproline II-like structure, it did not show the hypochromic
displacement seen with the native p31-43 peptide (Figure 2B).
Given this evidence that p31-43 might show a selective ability
to self-organize in solution, we next used transmission electron
microscopy (TEM) to analyze this in more detail. This showed
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FIGURE 2 | Structural analysis of p31-43 by circular dichroism shows polyproline II structures. (A) Circular dichroism spectra obtained using 10µM (15.3µg/mL),
50µM (76.5µg/mL), and 100µM (153µg/mL) solutions of peptide at 4◦C. A negative band at 205 nm together with a positive one 225 nm indicates the presence a
polyproline II structure, while the hypochromic shift of the bands indicates a self-assembly process. Results shown are representative of three independent
experiments. (B) Circular dichroism analysis of p31-43, inverted peptides (PI) and scrambled peptides (SP) at 100µM (153µg/mL) at 4◦C. In the scrambled peptide a
negative band at 203 nm is indicative of a random secondary structure, while the negative band at around 204 nm and the positive one at 225 nm in the p31-43 and
inverted peptides is indicative of a polyproline II conformation. p31-43 shows a hypochromic displacement of the negative band with respect to the inverted peptide,
suggesting a self-organization process in p31-43. Results are representative of three independent experiments.
FIGURE 3 | Oligomeric p31-43 structures characterized by TEM. Samples of p31-43 were prepared in MilliQ water and deposited on a grid covered with formvar. (A)
Representative image showing the presence of oligomeric structures in a 50µM (76.5µg/mL) solution. (B) Size distribution of the oligomers observed in (A), showing
a mean diameter of 13.6 ± 3.4 nm. (C) Representative image showing the presence of oligomers in a 100µM (153µg/mL) solution. (D) Size distribution of the
oligomers observed in (C), showing a mean diameter of the structures is 17 ± 7 nm.
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FIGURE 4 | In-silico modeling of p31-43 aggregation. (A) Left: cartoon representation of the initial (helical) conformation used as starting conformer. For visual clarity,
only Prolines are shown. Right: four different conformers arbitrarily chosen along the simulation of the isolated peptide and used to generate the initial configuration of
the system containing 50 copies of p31-43 [inset indicated with 0ms in panel (B)]. The cartoons show the conserved presence of polyproline. (B) Mean cluster sizes
of aggregates formed before (bottom right) and during simulation (top left) using 50 copies of p31-43. Individual peptide copies are identified by different colors. (C)
The final state is shown (left), with structural convergence within the aggregate being highlighted by superposition of individual copies within a maximum root mean
square deviation of 0.1 nm, which corresponds to 41 out 50 peptides (right).
that at 50µM concentration, the peptide formed spherical
oligomers randomly distributed (Figure 3A). These oligomers
had an average diameter of 13.6 ± 3.4 nm (Figure 3B), while the
similar oligomers formed at 100µM had higher mean diameters
(17± 7 nm) (Figures 3C,D).
Together these studies show that p31-43 peptide can adopt
a polyproline II structure which is able to self-organize and
generate complex nanostructures in vitro.
In silico Modeling of p31-43 Oligomers
To gain further insights into the molecular determinants of p31-
43 aggregates, we undertook in silico modeling of the structures
formed by the peptide. When a single copy of the peptide
was arbitrarily assumed to start in a helical state, it was found
to be highly flexible (Supplementary Movie 1), spontaneously
acquiring random coil conformations, with the exception of the
central Pro36, Phe37, Pro38 residues, which retained a nearly
helical conformation (Figure 4A). In contrast, when multiple
copies of p31-43 were simulated together, they underwent
spontaneous aggregation, via formation of small clusters that
eventually fused into one single aggregate (Figure 4B). The
non-monotonic variation of the mean cluster size suggests that
spontaneous dissociation events also take place in solution. The
final aggregates had a prolated shape, with major and minor
diameters of 10.1 nm ± 0.2 and 6.9 nm ± 0.1, respectively,
comparable to the smaller oligomers found by TEM (Figure 3).
In contrast with the isolated peptide, multimer p31-43 copies
showed structural convergence, as shown by superposition of
individual monomers in the final conformation (Figure 4C and
Supplementary Movie 2). These aggregates exhibited an increase
in the amount of polyproline II conformation compared with
the monomers. Glutamine-glutamine interactions accounted for
around one fifth of the total contacts between individual peptide
strands in the aggregate (20% ± 1.6), while glutamine residues
were not involved in almost half of these contacts (45% ± 1.8).
This suggests that although the peptide may have an intrinsic
tendency to form aggregates, these may have a rather loose
structure.
p31-43 Activates the Apoptosis-Associated
Speck-Like (ASC) Complex in vitro and
Drives Production of IL-1β in vivo
We next asked whether activation of the innate immune response
and induction of enteropathy by p31-43 were related to its ability
to form aggregates with a defined nanostructure. The nucleotide-
binding domain, leucine-rich repeat-containing-like receptors
(NLRs) are cytosolic sensors that drive innate immunity by
mediating recognition of other kinds of particulate materials
including protein fibrils and of signals derived from organelles
damaged by these material (11). Therefore, we examined the
role of the NLRP3 inflammasome and its downstream effector
molecule caspase-1 in the effects of p31-43.
As we wished to avoid potentially confounding effects of
surgery on the activation of the NLRP3 inflammasome, we
decided to use the oral route for administering peptide in these
studies. Preliminary experiments showed that administration
of 2–20 µg p31-43 to wild type C57Bl/6 mice by oral gavage
reproduced the changes in V/C ratio and number of IELs in the
proximal small intestine that we had found when p31-43 was
given intraluminally (Figure 7 and Supplementary Figure 1).
The effects were dose dependent and we used the optimal dose
of 20 µg peptide in subsequent experiments.
The changes in V/C ratio and IEL counts found 16 h
after oral administration of 20 µg p31-43 to WT mice were
accompanied by increased mucosal levels of mature IL-1β,
together with a parallel decrease in the levels of pro-caspase 1,
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FIGURE 5 | Oral administration of p31-43 induces caspase 1 activation and production of mature IL-1β. (A) Western blot analysis of mature IL-1β and (B) caspase-1
and pro-caspase-1 quantification in whole small intestinal tissue from p31-43 or vehicle-fed mice 16 h after treatment. (C) IL-1β/caspase 1 ratio of data shown in
(A,B). (D) Representative results of Western blots are shown. Results shown are means ± 1 SEM for 5 mice and are representative of two experiments. **p < 0.01,
***p < 0.001, Student’s t-test.
FIGURE 6 | p31-43 induces ASC speck formation in vitro. (A) Human THP-1 ASC speck reporter cells were preconditioned for 3 h with LPS before addition of
different amounts of p31-43 for a further 16 h. Positive control cells (DNA) were transfected transiently with bacterial plasmid before addition of LPS. Cells showing
ASC specks were assessed by immunofluorescence and expressed as positive cells/100 total cells. Results shown are means ±1 SEM for three replicates/group and
are representative of two experiments **p < 0.01; ***p < 0.0001, ANOVA. (B) Representative images of ASC speck expressing cells (green) (blue–DAPI).
and correlation between caspase 1 and IL-1β levels (Figure 5).
Thus, the increment of IL-1β indicates the activation of the
inflammasome caspase-1 pathway in the small intestine mucosa
by oral administration of p31-43.
The inflammasome acts by recruiting a protein complex
that contains the apoptosis-associated speck-like (ASC) protein.
Therefore, to confirm that p31-43 can activate this complex,
we used a THP1 cell line expressing ASC-GFP that allowed the
resulting specks to be visualized by fluorescence microscopy.
In these experiments, the inflammasome was first “primed” by
pre-incubation of the THP1-ASC-GFP cells with LPS before
addition of peptide. Under these conditions, p31-43 induced
dose dependent increases in speck formation compared with
cells challenged with PBS alone (Figure 6). This effect was not
observed with the inverted peptide (Supplementary Figure 2).
Small Intestinal Damage Induced by
p31-43 Requires NLRP3 and Caspase-1
As these results suggested that p31-43 might activate the
inflammasome in vivo and in vitro, we assessed whether the
NLRP3 inflammasome was involved in the pathological effects of
p31-43 in the small intestine. In support of this idea, Nlrp3−/−
and caspase-1−/− mice did not develop altered V/C ratios
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FIGURE 7 | Enteropathy induced by p31-43 requires NLRP3 and caspase 1.
Morphological analysis of proximal small intestine of C57BL/6, NLRP3−/−,
and caspase 1−/− mice, 16 h after oral administration of 20 µg p31-43 or
PBS, showing mean IEL/100 enterocytes (left axis) and villus/crypt ratios (right
axis). Results shown are means ± 1 SEM for 6 mice/group. *p < 0.05.
or increases in IELs 16 h after feeding p31-43 (Figure 7) and
administration of the irreversible inhibitor of caspase-1, Ac-
YVAD-cmk, prevented these changes in WT mice fed p31-43
(Figure 8 and Supplementary Figure 3). Thus, the enteropathy
induced in vivo by p31-43 is dependent on NLRP3 and caspase 1.
DISCUSSION
Due to their unusual sequence, gluten peptides are resistant
to proteolytic enzymes in the gastrointestinal tract and several
peptides of reasonable length may remain undigested in the
intestinal lumen. Amongst these is the p31-43 peptide from
gliadin which has been detected intact after extensive digestion
by a combination of gastric, pancreatic, and brush border
enzymes (17). In vitro and ex vivo assays have shown that p31-
43 gliadin has proinflammatory and toxic effects (5). De Ritis
et al. (18) reported morphological alterations in enterocytes
when duodenal samples from untreated CD patients were
incubated with p31-55 gliadin peptide, which contains the p31-
43 sequence. Using organ culture, it was observed that p31-
43 induces the expression of HLA-DR molecules, a sign of
inflammatory response, in epithelial cells in the crypts (19) and
the expression of IL-15, CD83, cyclo-oxygenase 2 in lamina
propria cells together with enterocyte apoptosis (4, 5).
Efforts to identify a receptor for p31-43 have been
unsuccessful and recent reports suggest that it may be
internalized into early endosomes after direct interaction
with the cell membrane (7, 20) There, the peptide interferes
with vesicle trafficking leading to overactivation of the IL-15
and EGF pathways (21) and also to ER-stress (22). We have
shown previously that intestinal administration of p31-43
produces pathology in the small intestine, characterized by
reduction in the V/C ratio, increased number of IELs, induction
of inflammatory mediators and cell death in the proximal small
intestine. Although all these effects were MyD88 and Type I IFNs
dependent (6) it remains unclear how a 13 amino acid peptide
can have such potent effects on the innate immune system.
As this gliadin-derived peptide consists of an unusual amino
acid sequence, with a high content of glutamine and proline
residues (8) we explored if this was related to its immunological
properties. The assessment of conformational structure of gluten
proteins by different techniques (12, 23, 24) showed that the large
repetitive regions are in balance between β-turn and polyproline
II conformations, while non-repetitive regions adopt α-helix or
random conformation.
Our first experiments showed that the effects of p31-43
in vivo were not replicated by peptides with an inverted or
scrambled sequence, suggesting that a specific conformation of
this sequence might be the critical property. To test this idea,
we used biophysical approaches to evaluate the structure of p31-
43. Circular dichroism analysis showed that p31-43 presents
a polyproline II secondary structure in all the concentrations
we studied. These structural characteristics were not observed
for the scrambled peptide, but were found with the inverted
peptide which shares many critical positions of the p31-43
sequence (xxQQxPFPxQQxx). Therefore, these residues may
drive the formation of a polyproline II structure. However, an
important difference between the peptides was that only the
native one showed hypochromic properties when the spectra
were compared, suggesting that it may undergo self-assembly
in solution. Similar behavior has been reported for a number
of other proteins and peptides that are able to self-organize,
such as the amyloidogenic exon-30 of tropoelastin (16) and
the 33-mer gliadin peptide (9). These findings were supported
by TEM analysis which showed that p31-43 spontaneously
forms oligomeric nanostructures, whose size depends on the
peptide concentration. The results also suggested that the larger
aggregates may be generated by association or coalescence of
smaller ones, a self-assembly process that has been found using
similar approaches with proteins and peptides such as β-amyloid
(25), elastin like peptides (26), and the 33-mer gliadin peptide (9).
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FIGURE 8 | Enteropathy induced by p31-43 is prevented by inhibition of caspase 1. Villus/crypt rations (A) and intraepithelial lymphocyte counts (B) in the proximal
small intestine of C57BL/6 mice fed 20 µg p31-43 or PBS that had been treated ip 30min earlier with either 8 mg/kg of the Ac-YVAD-cmk caspase 1 inhibitor or with
DMSO. Results shown are means ± 1 SEM for 5 mice/group assessed 16 h after feeding p31-43 and are representative of two experiments. *p < 0.05, **p < 0.01,
ANOVA, Post-test Bonferroni.
Coarse grained molecular dynamic simulation in silico
confirmed the tendency of p31-43 to adopt a polyproline
II structure, before assembling spontaneously into small
clusters and then into larger structures. Altogether, in
silico studies correlating with results obtained by Circular
Dichroism, Transmission Electron Microscopy and Atomic
Force Microscopy (not shown) point out that p31-43 is able
to self-organize and form nanostructures (Herrera et al.,
manuscript in preparation). Formation of a polyproline II
structure appears to be a critical component of the pathology
in diseases associated with accumulation of misformed proteins
such as neurodegenerative diseases (27). Additional studies
by CD, AFM, DLS and molecular simulations extended the
characterization of p31-43 structure (Herrera et al., manuscript
in preparation). This ability to form ordered nanostructures
may help explain previous findings that p31-43 resists lysosomal
degradation, preventing vesicular trafficking and maturation,
leading to destabilization of vesicles, intracellular stress and
increased levels of reactive oxygen species (20, 28). As there is
no evidence for a specific receptor interacting with p31-43 (7) it
was unclear how this process might provoke an innate immune
response and one possibility we considered was activation of
the NLRP3 inflammasome. This family of cytosolic pattern
recognition receptor (PRR) complexes mediates the innate
immune response to other particulate materials such as uric acid
crystals and after intracellular stress insults such asmitochondrial
damage or changes in local K+ levels (11). Furthermore, the
NLRP3 inflammasome has been linked to chronic inflammatory
disorders based on protein aggregation such as Alzheimer’s
and Parkinson’s diseases (29). Here, we extend these findings
by showing that p31-43 activated the inflammasome in THP1
macrophage-like cells in vitro and that the acute mucosal
damage induced by p31-43 in vivo was absent in mice lacking
NLRP3 or its downstream mediator caspase-1. Pharmacological
inhibition of caspase-1 also prevented p31-43 induced pathology
in wild type mice. In parallel, this acute mucosal injury was
associated with increased levels of mature IL-1β, a cytokine
whose production requires cleavage by caspase-1 and is a
characteristic feature of inflammasome dependent innate
immune responses (30). Interestingly, previous studies have
reported that a complex mixture of gluten peptides stimulated
IL-1β release by peripheral blood mononuclear cells from Celiac
disease patients and that their analogous effects on murine
bone marrow derived dendritic cells required NLRP3 (31, 32).
Our findings indicate that the p31-43 peptide of α-gliadin
may account for at least part of this effect, although whether
other components of gluten also contribute remains to be
determined.
In conclusion, we propose that p31-43 plays a central role in
the pathogenesis of Celiac disease at least in part via an intrinsic
ability to form oligomers of polyproline II-like structures that
self-assemble and drive an NLRP3-caspase 1 dependent innate
immune response in the intestinal mucosa. However, it is
important to note that a variety of other triggers may be required
to initiate overt inflammation in the mucosa, either alone or
acting in synergy with each other. Indeed, it is known that
activation of the inflammasome occurs in two stages, “priming”
by PRR mediated activation of NF-κB activation, followed by
the NLR ligands themselves (30). In this respect, we have shown
previously that the MyD88 is required for the biological effects
of p31-43 in vivo (6). The type I IFN pathway is a further
aspect of the innate immune response that is induced by p31-
43 in vivo (6) and high levels of expression of IFNα and the
type 1 IFN pathway adaptor protein MxA are seen in duodenal
mucosa from Celiac disease patients (33). Inflammatory signals
triggered via the IFNαR, perhaps in enterocytes, could amplify
further the innate immune response induced by p31-43. Further
studies are needed to characterize the cells participating in the
sensing of p31-43 nanostructures. It is also important to note
that p31-43 may not be the only stimulus of innate immunity in
Celiac disease, with other possibilities including wheat amylase
trypsin inhibitors (34), viral infections (35), and bacterial
dysbiosis (36). Generation of a local inflammatory response by
factors such as these favors the induction of adaptive immune
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responses to gluten in genetically susceptible individuals, leading
to permanent disease. It is tempting to speculate that p31-43
may also contribute to the pathogenesis of non-celiac gluten
sensitivity (NCGS) another form of gluten intolerance with a high
prevalence (up to 6% of general population) whose pathogenesis
remains to be determined. However, it has been suggested that it
may reflect an innate response to gluten occurring in isolation
without generation of the adaptive immune response seen in
CD (37). Together these results underline the importance of
understanding the innate response and its triggers in different
gluten-related disorders.
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